Genzyme Corporation

Aug 06, 08 NEW STORY 14:07 ET Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen   Jul 23, 08 08:30 ET Genzyme Reports Strong Second-Quarter Growth   Jun 24, 08 08:00 ET Genzyme and Isis Complete Licensing of Mipomersen   Jun 17, 08 08:29 ET Genzyme Files Applications for Approval of Mozobil in the United States and Europe   Jun 02, 08 14:56 ET Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients   May 07, 08 14:00 ET Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease   Apr 25, 08 07:00 ET FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen   Apr 23, 08 08:30 ET Genzyme Reports Strong First-Quarter Growth   Apr 22, 08 08:37 ET Genzyme to Build New R&D Center in Beijing   Apr 21, 08 16:00 ET Genzyme Provides Update on Myozyme(R) Manufacturing   Apr 14, 08 08:55 ET Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy   Mar 19, 08 12:00 ET Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients   Mar 10, 08 08:58 ET Genzyme Announces Presentation of New Positive Data on Carticel(R)   Mar 06, 08 09:24 ET Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients   Feb 13, 08 08:30 ET Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year   Feb 01, 08 09:10 ET Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration   Jan 15, 08 08:30 ET Genzyme Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Lung Cancer Diagnostic   Jan 08, 08 11:55 ET Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue   Dec 19, 07 08:46 ET Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)   Dec 17, 07 09:31 ET Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation   Dec 13, 07 08:38 ET Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints   Dec 05, 07 09:48 ET Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML   Dec 04, 07 08:54 ET National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment   Nov 13, 07 09:03 ET Genzyme Receives FDA Response Letter on Synvisc-One(TM)   Oct 29, 07 09:31 ET Epicel(TM) Wins Marketing Approval for Severe Burn Victims   Oct 25, 07 09:36 ET Genzyme and Sunway to Collaborate on Gene Therapy Program in China   Oct 24, 07 08:49 ET Genzyme Reports Strong Earnings Growth in Third Quarter   Oct 23, 07 09:05 ET Genzyme Launches Cholestagel(R) in Europe   Oct 22, 07 16:50 ET Bioenvision Shareholders Approve Acquisition by Genzyme Corporation   10:02 ET FDA Approves Genzyme's Renvela(TM) for Dialysis Patients   Oct 16, 07 17:56 ET Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease   Oct 15, 07 02:00 ET Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis   Oct 12, 07 15:48 ET Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease   10:07 ET Genzyme Recognized by Scientists as a Top Employer   Oct 11, 07 15:10 ET Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS   Oct 10, 07 14:57 ET Delaware Court Approves Bioenvision, Genzyme Joint Petition   Oct 04, 07 16:04 ET Genzyme Receives Approval to Market Elaprase(R) in Japan   Sep 27, 07 08:45 ET Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share   Sep 26, 07 08:00 ET Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis   Sep 18, 07 10:30 ET Genzyme Begins Major Expansion of Boston Manufacturing Facility   Aug 09, 07 16:17 ET Genzyme Announces Settlement of Lawsuit Concerning Consolidation of Tracking Stocks   Aug 02, 07 09:01 ET Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint   Jul 25, 07 08:30 ET Genzyme Reports Significant Earnings Growth in Second Quarter   08:30 ET See 10Q or http://www.genzyme.com/corp/media/GENZ%20PR-072507.asp for Q2 2007 GAAP figures.   Jul 23, 07 09:00 ET Oswaldo Cruz Foundation and Genzyme Corporation Form Collaboration To Advance New Drugs for Neglected Diseases   Jul 19, 07 08:59 ET Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin's Lymphoma Meets Primary Endpoint   Jul 16, 07 09:00 ET Genzyme Announces Positive Results from Carticel(R) Study at Major Sports Medicine Meeting   Jul 10, 07 09:27 ET Genzyme Completes Tender Offer to Acquire Bioenvision, Inc.   Jul 06, 07 08:45 ET Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea   Jul 05, 07 09:14 ET Genzyme Announces Results of Clinical Trial of Hylastan   Jul 02, 07 09:45 ET Genzyme Extends Tender Offer to Acquire Bioenvision, Inc.   Jun 27, 07 12:30 ET Genzyme Corporation Moves Closer to Acquiring Bioenvision, Inc.   Jun 25, 07 09:00 ET Genzyme Receives FDA Approval for New Labeling for Carticel(R)   Jun 21, 07 09:07 ET Ceregene and Genzyme Announce Partnership for the Development and Commercialization of Cere-120 for Parkinson's Disease   Jun 20, 07 10:15 ET Genzyme Files for Approval of Single-Treatment Synvisc-One(TM)   Jun 18, 07 09:13 ET Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate   Jun 07, 07 09:01 ET Genzyme to Build New Biomanufacturing Plant to Support Growth of Thymoglobulin(R)   May 29, 07 09:09 ET Genzyme Corporation to Acquire Bioenvision, Inc.   08:00 ET Genzyme Announces $1.5 Billion Share Repurchase Authorization   May 22, 07 09:04 ET Genzyme Announces Publication in PNAS Describing Novel Gene Therapy Approach for Niemann Pick Disease   May 16, 07 12:00 ET Genzyme Announces Positive Initial Observations in Trial Evaluating Novel Oral Treatment for Gaucher Disease   May 09, 07 13:55 ET Genzyme Honored with James D. Watson Helix Award for Biotechnology Industry Leadership   May 02, 07 09:07 ET Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN   Apr 25, 07 08:47 ET Genzyme Reports Significant Revenue and Earnings Growth in First Quarter   Apr 16, 07 09:00 ET Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease   Apr 04, 07 08:00 ET Genzyme Files for Expanded Label for Campath(R) as First-Line Treatment For B-CLL Patients   Feb 28, 07 16:28 ET Genzyme Phasing in Annual Elections of Directors   Feb 14, 07 08:23 ET Genzyme Reports Financial Results for Fourth Quarter of 2006 and Full Year   Jan 15, 07 09:00 ET Genzyme Announces Publication of Study Showing Impact of Cerezyme on Bone Health for Patients With Type 1 Gaucher Disease   Jan 09, 07 11:49 ET Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude Productive Year   Jan 08, 07 09:00 ET Renagel in New Dialysis Study Published in Kidney International   Dec 21, 06 09:00 ET Genzyme Files for Approval of Sevelamer Carbonate for Patients on Dialysis   Dec 15, 06 08:07 ET Genzyme Retains Separate Medicare Code and Reimbursement Rate for Synvisc   Dec 11, 06 11:00 ET Data From Phase III Comparative Study Show Campath(R) Superior to Chlorambucil as a First-line Therapy in B-CLL   Nov 30, 06 13:17 ET Study Demonstrates One Administration of Synvisc Improves Osteoarthritis Pain   Nov 27, 06 11:24 ET Genzyme Begins Phase 2 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia   Nov 16, 06 09:07 ET Decreased Hospitalizations and Health Care Costs Associated with Renagel Use   Nov 09, 06 08:39 ET Study in Today's New England Journal of Medicine Shows Benefits of Thymoglobulin Use   Nov 07, 06 16:57 ET Genzyme Completes Tender Offer for Outstanding Shares of AnorMED   00:01 ET Genzyme and AnorMED Announce Completion of Hart-Scott-Rodino Review   Oct 31, 06 08:53 ET Genzyme Launches New Cystic Fibrosis Gene Sequencing Test   Oct 30, 06 08:47 ET Genzyme to Challenge Medicare Code and Reimbursement Decision for Synvisc   Oct 27, 06 14:09 ET Genzyme Extends Deadline for Tender Offer to Acquire AnorMED Inc.   Oct 18, 06 08:53 ET Medicines for Malaria Venture, Genzyme Corporation and the Broad Institute Expand Collaboration to Discover New Drugs for Malaria   Oct 12, 06 09:01 ET Genzyme Reports Strong Third-Quarter Financial Results   Oct 10, 06 09:50 ET Genzyme Announces Proposal to Increase Its Offer to Acquire AnorMED to $13.50 Per Share in Cash   Oct 06, 06 11:41 ET Genzyme Extends Deadline for Tender Offer to Acquire AnorMED Inc.   Oct 02, 06 09:17 ET Genzyme Receives European Approval for Synvisc(R) In Ankle and Shoulder Osteoarthritis Indications   Sep 14, 06 09:00 ET Genzyme Reports Interim Results from Trial of Campath(R) for Multiple Sclerosis   Sep 06, 06 09:03 ET Genzyme Begins Phase 3 Pivotal Study of Clolar(R) in Adult Acute Myelogenous Leukemia   Aug 31, 06 09:05 ET Genzyme Commends New Book for Portraying Challenges Faced by Patients with Pompe Disease and Their Families   Aug 30, 06 10:19 ET Genzyme to Initiate Tender Offer to Acquire AnorMED, Inc.   Aug 15, 06 08:59 ET Results of Phase 2 Study of Tolevamer for C. difficile-Associated Diarrhea Published in Clinical Infectious Diseases   Aug 11, 06 09:04 ET Genzyme Files for European Approval of Synvisc(R) In Ankle and Shoulder Indications   Jul 27, 06 09:01 ET Genzyme Launches New Diagnostic Test for Common Blood Cancer   Jul 26, 06 09:00 ET Genzyme Begins Phase 2 Trial of Oral Treatment for Gaucher Disease   Jul 24, 06 09:17 ET Genzyme Receives Approval for Additional Manufacturing at Ireland Plant   Jul 12, 06 08:34 ET Genzyme Reports Second-Quarter Financial Results   Jun 23, 06 09:21 ET Positive Synvisc Data Presented at European Conference   Jun 03, 06 15:00 ET Genzyme and Berlex Oncology Announce Interim Results of Campath in First-Line Study of Chronic Lymphocytic Leukemia at ASCO   May 17, 06 09:01 ET Genzyme Releases Two New Molecular Tests for Acute Myelogenous Leukemia   Apr 28, 06 13:00 ET FDA Approves Genzyme's Myozyme(R) for All Patients with Pompe Disease   Apr 19, 06 08:52 ET Genzyme Reports Financial Results for the First Quarter of 2006   Apr 13, 06 10:00 ET Genzyme Gives $2 Million Gift to Museum of Science   Apr 12, 06 10:53 ET Genzyme Launches Initiative to Assist the Development of Treatments for Neglected Diseases   Apr 10, 06 17:00 ET Genzyme Launches Initiative to Assist the Development of Treatments for Neglected Diseases   Apr 03, 06 09:03 ET European Commission Approves Genzyme's Myozyme(R)   Feb 28, 06 10:15 ET Richard F. Syron Elected to Genzyme's Board of Directors   Feb 23, 06 09:01 ET Genzyme Ends Enrollment in Phase 2 Trial of Cardiac Cell Therapy   Feb 15, 06 08:57 ET Genzyme Reports Financial Results for Fourth Quarter of 2005 and Full Year   Feb 09, 06 09:01 ET Genzyme Launches Key Test to Monitor Gleevec(R) Resistance   Feb 01, 06 09:34 ET Genzyme Granted Label Change for Thyrogen   Jan 27, 06 09:30 ET Myozyme(R) Receives Positive Opinion from European Regulatory Committee   Jan 17, 06 08:51 ET Genzyme Provides Update on U.S. Marketing Application for Myozyme(R)   Jan 10, 06 10:38 ET Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue   Jan 09, 06 12:29 ET Genzyme Named One of FORTUNE's '100 Best Companies to Work For'   Dec 21, 05 08:31 ET Genzyme Acquires Avigen's Gene Therapy Technology   Dec 06, 05 09:02 ET Genzyme Launches Colorectal Cancer Test to Determine Appropriate Camptosar(R) Dosage   Nov 22, 05 09:10 ET Cell Genesys San Diego Manufacturing Operation Acquired by Genzyme   Nov 08, 05 10:27 ET Genzyme Retains Its Medicare Code and Reimbursement Rate for Synvisc   Oct 18, 05 08:37 ET Genzyme Delivers Strong Third-Quarter Results   Oct 06, 05 09:02 ET Genzyme Licenses Exclusive Rights to Chronic Myeloid Leukemia Markers   Oct 05, 05 09:02 ET Genzyme Expands its Research and Manufacturing Presence in Massachusetts   Sep 30, 05 09:02 ET Genzyme Recognized by Scientists as a Top Employer for Third Consecutive Year   Sep 28, 05 12:24 ET RenaMed Biologics and Genzyme Announce Worldwide Collaboration to Advance Investigational Treatment for Acute Renal Failure   Sep 27, 05 08:51 ET Genzyme Launches Exclusive Lung Cancer Test   Sep 22, 05 09:01 ET Genzyme Expands Global Infrastructure for Manufacturing, R&D   Sep 16, 05 07:00 ET Genzyme and Schering AG Announce Interim Results from Trial of Campath for Multiple Sclerosis   Sep 15, 05 10:06 ET Genzyme Begins Trial of Myozyme(R) for Patients with Late-Onset Pompe Disease   Sep 08, 05 09:52 ET Genzyme Center Earns Highest Environmental Rating From U.S. Green Building Council      Jul 29, 05 08:48 ET Genzyme Submits BLA for Myozyme(R) for Treatment of Pompe Disease   Jul 28, 05 08:30 ET Genzyme Announces Positive Results from DCOR Trial Favoring Use of Renagel   Jul 19, 05 08:32 ET Genzyme Launches Minimal Residual Disease Test for Common Leukemia   Jul 14, 05 08:44 ET Genzyme Reports Second-Quarter GAAP EPS of $0.46, Non-GAAP EPS of $0.57   Jul 13, 05 11:01 ET Genzyme and Project HOPE Partner to Rebuild Critical Health Care Programs in Tsunami-Affected Areas   Jun 30, 05 11:27 ET Genzyme, Bone Care International Announce Shareholder Approval of Merger   Jun 15, 05 09:10 ET Genzyme and Bone Care International Announce Completion of Hart-Scott-Rodino Review   May 05, 05 10:30 ET Positive Synvisc Data Published by Cochrane Collaboration   May 04, 05 09:21 ET Genzyme and Bone Care International Announce Merger Agreement ------------------------------------------------------ Genzyme to Acquire Bone Care, Adding Complementary Therapy to Renagel; Accelerates Commercial Entry into Earlier Stages of Chronic Kidney   May 02, 05 09:58 ET Genzyme Announces License Agreement for Exclusive Rights to Lung Cancer Markers ------------------------------------------------------------------- Massachusetts General Hospital and Dana-Farber Cancer Institute Grant Rights to Develop Diagnostic Test   Apr 26, 05 08:32 ET Genzyme Reports Interim Results from Pivotal Study of Myozyme(R)   Apr 21, 05 08:29 ET Genzyme Reports First-Quarter GAAP EPS of $0.36, Non-GAAP EPS of $0.51 ----------------------------------------------- Raises EPS Guidance for the Year   Apr 04, 05 09:02 ET Genzyme Announces Start of Phase 3 Study of Novel, Non-Antibiotic Therapy for C. difficile Associated Diarrhea   Mar 15, 05 08:05 ET Genzyme Files Form 10-K for 2004   Mar 03, 05 09:16 ET Genzyme Announces European Marketing Approval of Thyrogen for Use in Thyroid Cancer Ablation   Feb 24, 05 09:05 ET Genzyme Begins Phase 2 Gene Transfer Trial for Peripheral Arterial Disease   Feb 17, 05 08:55 ET Genzyme Delivers Excellent Fourth-Quarter and 2004 Performance ------------------------------------------------ Outlook for 2005 Highlights Continued Momentum   Feb 08, 05 08:45 ET Genzyme Acquires Verigen AG, Bolstering Global Orthopaedic Franchise   Jan 24, 05 19:37 ET Genzyme Files Suit Against TKT for Glucocerebrosidase Patent Infringement   Jan 11, 05 18:00 ET Genzyme Reports Strong Fourth-Quarter Revenue Growth   Jan 06, 05 10:00 ET Genzyme Completes Purchase of Synvisc Sales and Marketing Rights   Dec 29, 04 08:33 ET CLOLAR(TM) Wins FDA Approval for Most Common Pediatric Leukemia   Dec 21, 04 08:05 ET Genzyme Completes Acquisition of ILEX Oncology, Inc.   Dec 20, 04 12:15 ET Genzyme Files for European Approval of Myozyme(R) for Treatment of Pompe Disease   Nov 29, 04 09:30 ET Genzyme Recognized as a Top Employer by Scientists for Second Consecutive Year   Nov 04, 04 09:15 ET Genzyme to Acquire Synvisc Sales and Marketing Rights from Wyeth   Oct 29, 04 09:00 ET Investigators Announce First Results From RIND Study; Data Support Renagel Use in New Dialysis Patients   Sep 20, 04 09:15 ET Genzyme Launches the Renagel REACH Program Expanding Access for Medicare Beneficiaries   Sep 15, 04 09:20 ET Genzyme Updates Timeframe for Acquisition of ILEX Oncology   Sep 09, 04 12:52 ET Genzyme Successfully Completes Phase 4 Study of Fabrazyme(R)   Jul 15, 04 09:00 ET Genzyme Extends Humanitarian Partnership with Project HOPE ------------------------------------------------------------------------------ Gaucher Initiative Serving Patients Around the World   Jul 14, 04 08:33 ET Genzyme Achieves Excellent Growth in Second Quarter ------------------------------------------- Expects Strong Performance to Offset Impact of Planned ILEX Merger; Maintains Full-Year Non-GAAP EPS Guidance   Jun 16, 04 08:46 ET Genzyme's Thyrogen Ablation Study Meets Endpoint   May 27, 04 16:09 ET Gail K. Boudreaux Elected to Genzyme's Board of Directors   May 20, 04 09:14 ET Genzyme to Redeem 3 Percent Convertible Subordinated Debentures   Apr 26, 04 08:32 ET Genzyme and ILEX Receive Request for Additional Information from the Federal Trade Commission   Apr 23, 04 14:03 ET Genzyme Celebrates Opening of New Global Headquarters   Mar 15, 04 16:44 ET Genzyme Reports Impact of U.K. Judicial Decision   Feb 26, 04 16:10 ET Genzyme Corporation to Acquire ILEX Oncology, Inc.   Feb 19, 04 09:58 ET Genzyme Reports Financial Results for 2003 and Provides Guidance for 2004   Jan 29, 04 10:27 ET Genzyme Receives Approval to Market Fabrazyme(R) in Japan   Jan 14, 04 04:00 ET Genzyme to Establish Research Facility in Europe   Jan 13, 04 17:22 ET FTC Closes Review of Genzyme's Acquisition of Novazyme   Jan 12, 04 12:11 ET Genzyme Reports Strong Revenue Growth for Fourth-Quarter and 2003   Dec 12, 03 09:10 ET Genzyme Announces Start of Phase 1 Trial of Small Molecule Drug for Multiple Sclerosis   Dec 09, 03 12:47 ET Genzyme Announces Closing of Sale of Convertible Senior Notes ----------------------------------------------------------------- Initial Purchasers Exercise Option for Additional $90 Million   Dec 03, 03 16:02 ET Genzyme Announces Proposed Offer of Convertible Senior Notes   Nov 24, 03 09:30 ET Genzyme Initiates Pivotal Trial to Treat Pain Due to OA of the Hip   Nov 21, 03 09:53 ET Genzyme Receives Positive Opinion on Application to Market Cholestagel(R) in Europe   Nov 20, 03 11:43 ET FDA Advisory Panel to Discuss Hylaform(R) PMA Tomorrow   Nov 12, 03 14:51 ET Genzyme Announces Dismissal of Shareholder Lawsuit   Nov 11, 03 08:47 ET Genzyme Reports Data from Gene Therapy Trial for Peripheral Arterial Disease   Nov 05, 03 09:03 ET Genzyme Genetics Presents New Data Relating to Prenatal and Genetic Testing   Oct 20, 03 12:15 ET Genzyme Announces Positive Results from Phase 2 C. difficile Trial ------------------------------------------------------------------- Seeks to Partner for Further Clinical Advancement   Oct 15, 03 08:55 ET Genzyme Corp. Reports Financial Results for Third Quarter of 2003   Sep 15, 03 09:07 ET European Commission Approves Expanded Label for Genzyme's Cerezyme   Sep 11, 03 15:43 ET Genzyme Completes Tender Offer for Shares of SangStat Medical Corporation   Sep 10, 03 09:04 ET Genzyme Expands Myozyme(TM) Development Program for Pompe Disease   Sep 05, 03 09:02 ET Genzyme Genetics Licenses Colon Cancer Diagnostic Patent Rights to LabCorp and Baylor   Aug 11, 03 10:53 ET Genzyme to Host Conference Call to Discuss SangStat Research and Development Programs   Jul 16, 03 09:31 ET Genzyme Announces Expansion of Senior Management Team   Jul 01, 03 07:31 ET Genzyme Completes Transaction to Eliminate Tracking Stocks   Jun 19, 03 14:40 ET Request for Injunction Dropped in Shareholder Lawsuit   Jun 11, 03 12:10 ET Genzyme, BioMarin Receive Marketing Approval for Aldurazyme in European Union   Jun 10, 03 08:51 ET Genzyme Receives Positive CPMP Opinion in Europe for Broader Cerezyme Label   Jun 05, 03 09:56 ET Genzyme Corp. Presents Encouraging New Data in Treating Niemann Pick Disease   Jun 03, 03 17:22 ET Genzyme Announces Shareholder Lawsuit   May 29, 03 09:20 ET Genzyme Begins Enrolling Patients in Pivotal Pompe Disease Study   May 28, 03 16:32 ET Genzyme Announces Shareholder Lawsuit   May 08, 03 16:06 ET Genzyme to Eliminate Tracking-Stock Structure -------------------------------------------- EPS Guidance for 2003 Remains Unchanged   Apr 24, 03 15:59 ET Genzyme General Announces Conference Call Information Regarding Fabrazyme Approval   15:20 ET FDA Approves Genzyme's Fabrazyme(R)   Apr 16, 03 09:13 ET Genzyme Molecular Oncology Reports First Quarter 2003 Results ----------------------------------------------------------------------- Kidney Cancer Clinical Trial Enrolling Patients/Treatment Underway   09:11 ET Genzyme Biosurgery Reports First Quarter Revenue Growth ------------------------------------------------------------ Strong Performance of Synvisc and Sepra Product Lines Continues   09:09 ET Genzyme General Reports 30 Percent Increase in First-Quarter Revenues   Mar 27, 03 08:37 ET EMEA Approves Renagel(R) Production at New Genzyme Plant in Ireland   Mar 19, 03 09:07 ET Genzyme General Begins Enrolling Patients in Pompe Disease Study   Mar 18, 03 09:33 ET Genzyme Molecular Oncology Receives Patent Covering Novel Peptide Corresponding to HER-2   Mar 05, 03 14:16 ET Genzyme General Reports 2002 Fourth-Quarter and Full-Year Earnings   Feb 21, 03 13:03 ET BioMarin, Genzyme Announce Positive Opinion for Aldurazyme From European Regulatory Authority   Jan 15, 03 16:17 ET FDA Panel Backs Efficacy, Safety of Aldurazyme for MPS I   Jan 13, 03 19:19 ET FDA Advisory Committee Provides Positive Review of Fabrazyme(R) ----------------------------------------------------- Action on BLA Expected by end of April   Jan 10, 03 10:38 ET FDA Advisory Panel to Discuss Genzyme's Fabrazyme(R) BLA Monday   Jan 07, 03 09:42 ET Genzyme General Reports Fourth-Quarter and Full-Year Revenues for 2002 --------------------------------------------------------------------------- Views 2003 as a "Year of Momentum"   Dec 10, 02 09:11 ET Genzyme Biosurgery Launches Phase 2 Clinical Trial in Cardiac Cell Therapy   09:09 ET Genzyme Molecular Oncology Announces Completion Of Breast Cancer Vaccine Trial Data Presented at American Society of Hematology Conference   Oct 28, 02 13:07 ET BioMarin and Genzyme Announce FDA Panel Meeting for Aldurazyme   Sep 26, 02 09:11 ET Genzyme General Files to Market Cholestagel(R) in Europe   Sep 20, 02 16:44 ET Genzyme Opposes Postponement of Advisory Panel Meeting   Sep 16, 02 02:01 ET Genzyme General Revises Financial Guidance for Third Quarter and Full Year   00:30 ET BioMarin and Genzyme's Application for Aldurazyme Accepted by the FDA and Granted Priority Review Status   Sep 09, 02 10:14 ET Long-term Success of Cerezyme Therapy Described in New Publication   Aug 27, 02 10:59 ET Genzyme Molecular Oncology Article Published on Powerful Discovery Method and Its Use In Cancer Vaccine Development   Jul 24, 02 08:54 ET Positive Synvisc Data Published in Osteoarthritis and Cartilage   Jul 17, 02 09:18 ET Genzyme Molecular Oncology Reports Second Quarter 2002 Results   09:12 ET Genzyme General Reports Second-Quarter Financial Results   Jul 09, 02 16:12 ET Genzyme Announces Management Appointments   Jul 08, 02 14:16 ET Genzyme Announces FDA Panel Will Review Fabrazyme BLA   Jun 27, 02 09:02 ET Genzyme Molecular Oncology Presents on Powerful Genomics Technology At Immunology Conference   00:01 ET Genzyme's Treat to Goal Study Published in Kidney International   Jun 24, 02 09:03 ET Genzyme Molecular Oncology and Silico Insights Sign Agreement To Co-Market Genomics Technologies   Jun 19, 02 16:01 ET Genzyme General Revises 2002 Financial Guidance   May 15, 02 11:48 ET Genzyme Reports FTC Review of Novazyme Acquisition   May 06, 02 09:45 ET New Genomics Method Likely to Accelerate Completion of the Human Genome   Apr 17, 02 09:07 ET Genzyme Biosurgery Reports Sound First Quarter ------------------------------------------------------- Synvisc, Sepra Revenue Up Significantly; Expenses Continue to Decline   09:05 ET Genzyme Molecular Oncology Reports First Quarter 2002 Financial Results ---------------------------------------------------------------- Rapid Progress Cited in the Clinic   09:04 ET Genzyme General Reports First Quarter Financial Results   Apr 15, 02 00:30 ET BioMarin and Genzyme Initiate "Rolling" BLA Filing for Approval to Market Aldurazyme in the United States   Apr 02, 02 16:22 ET Genzyme Molecular Oncology Licenses Rights to Gene Implicated in Colon Cancer Metastasis   Apr 01, 02 00:30 ET BioMarin and Genzyme File to Market Aldurazyme in Europe   Mar 27, 02 08:13 ET Genzyme General Takes Steps to Meet Demand for Renagel(R) ---------------------------------------------------- Adjusts First-Quarter Guidance; Reaffirms Guidance for the Year   Mar 07, 02 08:51 ET Genzyme Molecular Oncology Reports 2001 Financial Results -------------------------------------------------------- Progress Made in the Clinic and Through Partnerships   08:50 ET Genzyme Biosurgery Reports Solid First-Year Revenue -------------------------------------------------------- Operating Expenses Decline Steadily Throughout 2001   08:49 ET Genzyme General Reports 2001 Earnings at High End of Guidance -------------------------------------------------------- Revenues Increase 29 Percent   Feb 20, 02 08:52 ET Genzyme Molecular Oncology to Present at BIO CEO and Investor Conference   08:51 ET Study Published in Major Cardiology Journal Analyzes Cardiac Calcification Data Collected in Genzyme Trial   Feb 13, 02 13:32 ET Long-term Outcomes of Genzyme Biosurgery's Carticel(R) Described in Three Presentations Today   Feb 04, 02 08:48 ET Genzyme and Gambro Will Collaborate to Improve Phosphorus Management Among Dialysis Patients   Jan 24, 02 10:17 ET Genzyme General Provides 2002 Financial Guidance   Jan 17, 02 10:45 ET Genzyme to Spin Out Peptimmune   Jan 14, 02 10:04 ET Genzyme Molecular Oncology to Present at Wachovia Securities Integrated Oncology Conference   09:16 ET Genzyme Molecular Oncology Expands Antiangiogenesis Focus With Appointment of Teicher   Jan 03, 02 10:43 ET Genzyme Biosurgery to Present at JPMorgan H&Q Healthcare Conference   Jan 02, 02 14:21 ET Genzyme Genetics Purchases Cancer Diagnostics Rights from Genzyme Molecular Oncology   Dec 18, 01 09:42 ET Genzyme Molecular Oncology's SAGE(TM) Technology Highlighted In Article Published on Lung Cancer   Dec 14, 01 15:39 ET Genzyme Moves Toward Appeal in Patent Infringement Suit Against TKT   Dec 13, 01 11:16 ET Genzyme General to be Added to S&P 500 Index   Dec 11, 01 09:05 ET Genzyme Molecular Oncology Announces Presentation of Data From Two Cancer Vaccine Clinical Trials at ASH Conference   Dec 10, 01 06:00 ET Genzyme and Pharming Reach Agreement   Nov 19, 01 08:58 ET Genzyme Molecular Oncology and Kirin Form Partnership to Develop Antibody Therapeutics   Nov 12, 01 02:00 ET Genzyme General and Cambridge Antibody Technology Initiate Phase 1-2 Clinical Trial of CAT-192   Nov 02, 01 01:00 ET BioMarin and Genzyme to File for Marketing Approval for Aldurazyme(TM) Based on Phase 3 Trial Results   Oct 31, 01 15:48 ET Genzyme Biosurgery, Society of Thoracic Surgeons Launch New Effort to Track Thoracic Outcomes   Oct 30, 01 09:11 ET Genzyme Acquires Manufacturing Facility in Europe   Oct 24, 01 08:47 ET Genzyme Molecular Oncology Receives Patent for Newly Discovered Melanoma Immunogens   Oct 23, 01 10:34 ET Genzyme Molecular Oncology to Present at Techvest Emerging Healthcare Conference   Oct 22, 01 11:14 ET Genzyme General Receives Complete Response Letter for Fabrazyme(TM) BLA   Oct 18, 01 08:52 ET Genzyme Molecular Oncology Reports Third Quarter 2001 Results   08:51 ET Genzyme General Reports 33 Percent Increase In Third-Quarter Revenues   Oct 16, 01 10:23 ET Genzyme Molecular Oncology Presents Discovery of Antibody Targets At Anti-Cancer Conference   Oct 15, 01 10:12 ET Genzyme to Launch Thyrogen(R) in Europe   Oct 11, 01 12:06 ET Genzyme Concludes Treat-to-Goal Study   Oct 05, 01 12:32 ET Genzyme Biosurgery to Present at UBS Warburg Global Life Sciences Conference   Oct 02, 01 10:36 ET Genzyme Genetics Expands Cystic Fibrosis Testing Capabilities   Sep 28, 01 08:28 ET Genzyme Biosurgery Presents Today at Bear Stearns 'Virtual Healthcare Conference'   Sep 27, 01 10:16 ET Genzyme Completes Acquisition of Novazyme Pharmaceuticals   Sep 19, 01 12:05 ET Genzyme to Acquire Certain Assets of Pharming N.V.   Sep 12, 01 08:48 ET Genzyme Corp. Saddened by Death of Lisa J. Raines In Crash of American Airlines Flight 77   Sep 04, 01 11:52 ET Genzyme Molecular Oncology and the National Cancer Institute Sponsor SAGE 2001 Conference   Aug 15, 01 09:00 ET Genzyme General Receives Approval to Market Renagel(R) in Brazil   Aug 07, 01 09:30 ET Genzyme to Acquire Novazyme Pharmaceuticals   Aug 03, 01 08:52 ET Genzyme Receives Approval to Market Fabrazyme(TM) in Europe   Aug 02, 01 13:31 ET Genzyme Supports Senate Bill to Provide Medicare Coverage for Phosphate Control for Patients on Dialysis   Jul 19, 01 08:27 ET Genzyme Molecular Oncology Reports Second Quarter 2001 Results   08:26 ET Genzyme Biosurgery Reports Second Quarter Results   08:25 ET Genzyme General Reports 28 Percent Increase in Second-Quarter Revenues   Jul 11, 01 15:09 ET Genzyme Biosurgery is Added to Russell 2000 and 3000 Indexes   12:24 ET Genzyme Molecular Oncology is Added to Russell 2000 and 3000 Indexes   Jul 10, 01 10:35 ET Genzyme Diagnostics, SYN-X Pharma Reach New Agreement to Create a Point-of-Care Diagnostic Tool for Stroke   Jul 05, 01 08:42 ET Positive Phase 3 Results for Genzyme General's Fabrazyme(TM) Published in New England Journal of Medicine   Jun 26, 01 06:01 ET Genzyme Study Demonstrates Significant Impact of Renagel(R) On Cardiac Calcification   Jun 21, 01 09:01 ET Genzyme General Announces Results from Phase 4 Study of Thyrogen   Jun 13, 01 08:45 ET Genzyme General Announces Re-Launch of 800 mg Renagel(R) Tablet   Jun 04, 01 10:51 ET Genzyme and Focal Announce Progress on Merger   10:47 ET Genzyme Molecular Oncology Acquires Key Fusion Technology Patent Rights From BruCells, S.A./N.V. of Belgium   Jun 01, 01 12:32 ET Genzyme Completes Two-for-One Stock Split   May 31, 01 10:24 ET Genzyme Reports Progress in Gene Therapy Program   May 30, 01 10:08 ET Genzyme Reports Data Demonstrating Advantages Of Genz-78132 Over Other Substrate Inhibition Compounds   May 29, 01 12:32 ET Genzyme General Reports New Data from Fabrazyme(TM) Extension Study Showing Clearance of GL-3 from Broad Range of Cell Types   10:30 ET Genzyme Outlines Manufacturing Expansion Strategy   May 21, 01 16:43 ET Genzyme and Focal, Inc. Announce Filing of Registration Statement for Genzyme's Acquisition of Focal   08:24 ET Genzyme Study Finds That Testing For More Gene Mutations Could Improve Cystic Fibrosis Screening   May 15, 01 11:32 ET Genzyme Forms Collaboration With Zentaris, Expanding its Investment in Europe   May 14, 01 16:07 ET Genzyme Announces Closing of Sale of Convertible Subordinated Notes   May 08, 01 09:42 ET Genzyme to Acquire Wyntek   May 04, 01 09:47 ET Genzyme General Raises Guidance for Renagel(R)   May 03, 01 09:33 ET Genzyme Announces Pricing of Convertible Subordinated Notes   May 02, 01 16:12 ET Genzyme to Offer Convertible Subordinated Notes   16:12 ET Genzyme to Redeem 5.25 Percent Convertible Subordinated Notes   Apr 26, 01 09:15 ET Genzyme to Acquire Focal, Inc.   Apr 25, 01 11:01 ET Genzyme General Announces Two-For-One Stock Split   Apr 19, 01 08:12 ET Genzyme General's Revenues Increase 25 Percent in First Quarter   Apr 17, 01 18:09 ET Genzyme General and DaVita, Inc. to Collaborate on Program to Make Renagel Widely Available to Patients   Apr 05, 01 10:21 ET Mara Aspinall Named President of Genzyme Genetics   Apr 02, 01 13:49 ET Genzyme General Acquires Lisfarma   Mar 28, 01 11:40 ET Genzyme General Announces CPMP Positive Opinion for Fabrazyme   Mar 20, 01 11:30 ET Genzyme General and Pharming Report Publication of Study Results for Pompe Disease Therapy   Mar 16, 01 08:03 ET Genzyme and Diacrin Report Preliminary Results From Phase 2 Trial of NeuroCell(TM)-PD   Mar 15, 01 09:22 ET Genzyme Molecular Oncology Licenses Colon Cancer Diagnostic Patent Rights to Three Diagnostic Laboratories   Mar 08, 01 13:03 ET Genzyme General Reports Solid Revenue and Profit Growth in 2000   09:19 ET Genzyme Molecular Oncology Reports 2000 Financial Results   09:16 ET Genzyme Biosurgery Reports Fourth Quarter and 2000 Results   Feb 26, 01 07:58 ET Genzyme General Says Renagel Prescriptions Jumped 15% in January Prompting Increase in Renagel(R) Revenue Guidance in 2001   Feb 21, 01 14:31 ET Genzyme Appoints Former U.S. Senator Connie Mack to Board of Directors   Feb 16, 01 09:08 ET Genzyme General Provides 2001 Financial Guidance   Jan 18, 01 10:18 ET Genzyme General Begins Treating Fabry Patients in France Under an ATU   Jan 10, 01 16:09 ET Genzyme Molecular Oncology Announces HIV Antigen Discovery Collaboration with Dr. Bruce Walker of Massachusetts General Hospital   Jan 09, 01 18:05 ET Genzyme General Announces Record Fourth-Quarter and 2000 Revenues   Dec 26, 00 17:12 ET Genzyme General Reports Progress on FDA Review of Fabrazyme(TM) BLA   Dec 21, 00 09:11 ET Genzyme Molecular Oncology Reports Financial Guidance for 2001   Dec 19, 00 14:45 ET Genzyme Biosurgery Stock Starts Trading   Dec 18, 00 12:22 ET Genzyme Biosurgery Provides 2001 Financial Guidance   Dec 15, 00 15:38 ET Genzyme Shareholders Approve Creation of Genzyme Biosurgery   Dec 14, 00 16:21 ET Genzyme Completes Merger with GelTex   Dec 13, 00 17:42 ET Genzyme to Provide Financial Guidance for Genzyme Biosurgery and Genzyme Molecular Oncology   Dec 08, 00 13:23 ET Genzyme Corp. Reports ISS Recommends Formation of Genzyme Biosurgery   Nov 29, 00 07:30 ET Genzyme Surgical Products Receives Clearance to Market Innovative Valve Implantation System   Nov 27, 00 11:25 ET Genzyme General Strengthens Lysosomal Storage Disorder Program With License Agreement for Promising Small-Molecule Compounds   Nov 14, 00 16:30 ET Genzyme Files Suit Against Atrium for Patent Infringement   Nov 09, 00 15:14 ET Genzyme and GelTex Announce Registration Statement for Genzyme's Acquisition of GelTex Declared Effective by SEC   Nov 06, 00 08:34 ET Genzyme and Biomatrix Announce Registration Statement for Genzyme Biosurgery Declared Effective by SEC   Nov 01, 00 18:54 ET Genzyme and GelTex Announce Filing of Registration Statement for Genzyme's Acquisition of GelTex   17:03 ET Genzyme General Says Fabrazyme(TM) BLA Will Not Need December Advisory Committee Review   Oct 27, 00 10:12 ET Genzyme and Biomatrix Announce Filing of Amended Registration Statement for Genzyme Biosurgery and Biomatrix Merger   Oct 19, 00 08:47 ET Genzyme Corp. Announces Third-Quarter Financial Results for Genzyme General   08:46 ET Genzyme Corp. Announces Genzyme Molecular Oncology's Third Quarter Financial Results   08:45 ET Genzyme Corp. Reports Third Quarter Financial Results for Genzyme Tissue Repair   08:45 ET Genzyme Corp. Reports Third-Quarter Financial Results For Genzyme Surgical Products   Oct 18, 00 07:29 ET Genzyme Molecular Oncology and Purdue Pharma L.P. Announce Tumor Antigen Discovery and Licensing Agreement   Oct 17, 00 08:46 ET Genzyme Corp. Modifies Financial Statement Format   Oct 10, 00 09:08 ET Genzyme Molecular Oncology Expands Access to Its SAGE Genomics Technology with License to Invitrogen Corporation   Oct 05, 00 14:31 ET Results from Genzyme General's Pivotal Trial of Fabrazyme(TM) Presented at ASHG Meeting   Oct 03, 00 09:17 ET Genzyme Molecular Oncology Announces Initiation of Kidney Cancer and Melanoma Cancer Vaccine Clinical Trials   Oct 02, 00 11:57 ET Genzyme Surgical Products Initiates Second Cardiovascular Gene Therapy Clinical Trial   Sep 28, 00 02:00 ET Genzyme General and Cambridge Antibody Technology To Collaborate on Development of Human Anti-TGF-beta Monoclonal Antibodies   Sep 26, 00 13:05 ET Genzyme Surgical Products Wins Contract with Novation for Chest Drainage Devices